NURS 506 Week 3 Discussion Board Forum 2 on Viral Oncogenesis and Prevention Example

Discussion Board Forum 2: How HPV Turns a Cell Cancerous, and What Vaccination Has Shown

NURS 506 Advanced Physiology and Pathophysiology, Discussion Board Forum 2

Thread by [Student Name]

The classmates replied to are composites written for a model discussion.

Most cancers arise from mutations that accumulate over decades for reasons we only partly control. Cervical cancer is different: nearly every case traces back to a persistent infection with a high-risk human papillomavirus, which makes it one of the best examples in this week's chapters of carcinogenesis we can now prevent.

The mechanism shows how a virus can take over the cell cycle. High-risk types, especially HPV 16 and 18, infect the basal cells of the cervical epithelium through small breaks. In most people the immune system clears the infection within two years. When it persists, viral DNA can integrate into the host genome, often disrupting the viral gene that normally restrains production of two oncoproteins. E6 then binds p53, the protein that halts the cell cycle and triggers apoptosis after DNA damage, and targets it for degradation. E7 binds the retinoblastoma protein, which normally holds the transcription factor E2F in check, so the cell moves from G1 into S phase without its usual signal. With both brakes released, the cell keeps dividing, cannot repair its DNA and does not die, which is exactly the combination our textbook describes as the start of malignancy. E6 also activates telomerase, letting the cell divide indefinitely (McCance & Huether, 2019). Over years, these cells progress through intraepithelial neoplasia to invasive cancer.

Because the cause is known, prevention works, and recent population data show how well. Falcaro et al. (2024) analyzed English registry data on 29,968 cervical cancers and 335,228 grade 3 precancers and found that among women offered vaccination routinely at age 12 or 13, cervical cancer rates were 83.9% lower and grade 3 precancer rates 94.3% lower than in women never offered the vaccine. The effect held across all five levels of socioeconomic deprivation. A 2026 analysis of mortality went further: among women aged 20 to 24 between 2020 and 2024, about 88% to 90% of whom were vaccinated at 12 or 13, no cervical cancer deaths occurred, against roughly 23 expected from historical rates (Sasieni & Falcaro, 2026). Both studies are observational, so screening changes and other factors may contribute, but the size and consistency of the effect are striking.

For an advanced practice nurse, the application is clear. A strong, presumptive recommendation for vaccination at the routine adolescent visit is one of the most effective cancer prevention steps we can take, and parents respond better to "your child is due for the HPV vaccine today" than to an open question. Screening still matters for women vaccinated after exposure began and for those never vaccinated.

Paul urges us to honor God with our bodies (English Standard Version Bible, 2001/2016, 1 Corinthians 6:19-20). Preventing a cancer before it starts is one way of caring for the bodies entrusted to us and our patients, and the vaccine data are a reminder that knowledge of how cells fail can become a gift to a whole generation.

Reply to Jessica

Jessica, your point that HPV-related cancer is no longer mainly a women's disease is important and often missed. Oropharyngeal cancer of the tonsils and base of the tongue has now overtaken cervical cancer as the most common cancer linked to high-risk HPV in the United States, and it occurs mainly in men. Patel et al. (2026) used national cancer registry data from 2017 to 2021 to estimate the burden in disability-adjusted life-years among U.S. men and found that tonsillar cancers carried the largest burden, averaging 58,979 life-years lost to death and disability each year. The overall burden declined slightly, but it rose among men 65 and older, who were never eligible for the vaccine. The same E6 and E7 mechanism drives these tumors, which often express p16 as a marker of HPV involvement. For practice, that means recommending vaccination to boys as firmly as to girls, and thinking of HPV when an adult man without a smoking history presents with a persistent neck mass or sore throat. Have you seen parents hesitate more about vaccinating sons than daughters?

Reply to Daniel

Daniel, your question about whether vaccinated women still need cervical screening is one I hear from patients too. The answer for now is yes. Current vaccines do not cover every high-risk type, and many women in screening age groups were vaccinated after they may already have been exposed, or not at all. The English data you mentioned actually show this pattern: Falcaro et al. (2024) found that women offered catch-up vaccination at 16 to 18 saw smaller reductions in grade 3 precancer than those vaccinated at 12 or 13, which fits the idea that the vaccine prevents new infection but does not clear existing ones. As cohorts vaccinated early reach screening age, guidelines may lengthen intervals or start screening later, and some countries are already moving that way. Your suggestion to explain this to patients by comparing the vaccine to a seat belt and screening to a smoke detector is a good one, because both keep their value even when the other is in place. Have you found that patients understand why HPV testing has replaced the Pap test alone in many guidelines?

References

English Standard Version Bible. (2016). Crossway. (Original work published 2001)

Falcaro, M., Soldan, K., Ndlela, B., & Sasieni, P. (2024). Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: Population based observational study. BMJ, 385, Article e077341. https://doi.org/10.1136/bmj-2023-077341

McCance, K. L., & Huether, S. E. (2019). Pathophysiology: The biologic basis for disease in adults and children (8th ed.). Elsevier.

Patel, H. V., Laird, M. C., Crone, M. D., Hranjec, T., Motiani, V., Laxmidhar, F. M., Mohamed, I. E. E., Amaraneni, A., Patel, M. R., Ault, K. A., & Kroth, P. J. (2026). Disability-adjusted life-years from human papillomavirus-related oral cavity and pharynx cancers in US men, 2017-2021. Cancer, 132(9), Article e70412. https://doi.org/10.1002/cncr.70412

Sasieni, P., & Falcaro, M. (2026). Cervical cancer mortality trends following HPV vaccination in England, 2001-24: An analysis of population-based mortality data. The Lancet, 408(10550), 162-168. https://doi.org/10.1016/S0140-6736(26)00918-9